undamentalytics Newsletter

Amylyx Pharmaceuticals, Inc. valuation and forecast

Explore the models for Amylyx Pharmaceuticals, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Amylyx Pharmaceuticals, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Analyst recommendations

12 analysts, Oct 2026
Buy1192%
Hold18%
Sell00%

Monthly trend

  1. Oct 202611112
  2. Sep 202611112
  3. Aug 202611112
  4. Jul 202610111

Counts of recommendations published by analysts covering Amylyx Pharmaceuticals, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

AMLX valuation questions

How does Fundamentalytics value Amylyx Pharmaceuticals, Inc.?
We use the models that fit Amylyx Pharmaceuticals, Inc.'s business and available financial data. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved November 1, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Amylyx Pharmaceuticals, Inc.